| Biological Sciences | 2021-2025 | 58 | CN 20 | 99.95 |
| Medical and Health Sciences | 2021-2025 | 316 | CN 33 | 99.94 |
| Molecular Biology | Lifetime | 912 | CN 46 | 99.51 |
| Cancer Research | Lifetime | 149 | CN 6 | 99.18 |
| Oncology | Lifetime | 796 | CN 28 | 98.30 |
| Pathology and Forensic Medicine | Lifetime | 790 | CN 21 | 96.21 |
| Medical Genetics | Lifetime | 870 | CN 18 | 89.02 |
| Biotechnology | Lifetime | 895 | CN 57 | 73.65 |
| Molecular Biology | 2021-2025 | 29 | CN 13 | 99.89 |
| Cancer Research | 2021-2025 | 10 | CN 4 | 99.68 |
| Oncology | 2021-2025 | 138 | CN 15 | 99.02 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 167 | CN 24 | 98.78 |
| Surgery | 2021-2025 | 282 | CN 19 | 98.17 |
| Epidemiology | 2021-2025 | 278 | CN 27 | 97.77 |
| Immunology | 2021-2025 | 177 | CN 42 | 96.10 |
| Infectious Diseases | 2021-2025 | 304 | CN 32 | 94.36 |
| Pathology and Forensic Medicine | 2021-2025 | 195 | CN 23 | 94.54 |
| Cell Biology | 2021-2025 | 135 | CN 15 | 88.64 |
| Medical Genetics | 2021-2025 | 214 | CN 6 | 89.86 |
| Obstetrics and Gynecology | 2021-2025 | 390 | CN 16 | 70.79 |
| Cancer-related molecular mechanisms research | Lifetime | 62 | CN 22 | 99.62 |
| MicroRNA in disease regulation | Lifetime | 89 | CN 24 | 99.51 |
| Circular RNAs in diseases | Lifetime | 53 | CN 24 | 99.40 |
| RNA modifications and cancer | Lifetime | 270 | CN 25 | 99.35 |
| Epigenetics and DNA Methylation | Lifetime | 757 | CN 62 | 98.26 |
| Ferroptosis and cancer prognosis | Lifetime | 240 | CN 113 | 97.03 |
| Cancer-related gene regulation | Lifetime | 381 | CN 39 | 98.02 |
| COVID-19 Clinical Research Studies | Lifetime | 789 | CN 117 | 97.27 |
| Cancer Cells and Metastasis | Lifetime | 490 | CN 24 | 97.91 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 960 | CN 62 | 97.80 |
| Ubiquitin and proteasome pathways | Lifetime | 559 | CN 47 | 97.61 |
| Cancer, Lipids, and Metabolism | Lifetime | 581 | CN 15 | 97.88 |
| Peptidase Inhibition and Analysis | Lifetime | 818 | CN 25 | 97.42 |
| Extracellular vesicles in disease | Lifetime | 439 | CN 131 | 96.57 |
| Cancer-related Molecular Pathways | Lifetime | 698 | CN 30 | 97.70 |
| Cancer Mechanisms and Therapy | Lifetime | 312 | CN 45 | 96.75 |
| Histone Deacetylase Inhibitors Research | Lifetime | 672 | CN 65 | 94.46 |
| Wnt/β-catenin signaling in development and cancer | Lifetime | 541 | CN 29 | 94.61 |
| Hippo pathway signaling and YAP/TAZ | Lifetime | 383 | CN 30 | 93.29 |
| Protein Tyrosine Phosphatases | Lifetime | 690 | CN 53 | 88.50 |
| FOXO transcription factor regulation | Lifetime | 910 | CN 194 | 74.42 |
| Mechanisms of cancer metastasis | Lifetime | 802 | CN 173 | 62.30 |
| RNA modifications and cancer | 2021-2025 | 15 | CN 9 | 99.81 |
| Cancer-related molecular mechanisms research | 2021-2025 | 15 | CN 10 | 99.80 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 18 | CN 9 | 98.92 |
| Cancer-related gene regulation | 2021-2025 | 10 | CN 6 | 99.14 |
| MicroRNA in disease regulation | 2021-2025 | 35 | CN 18 | 99.40 |
| Ubiquitin and proteasome pathways | 2021-2025 | 19 | CN 6 | 98.62 |
| Epigenetics and DNA Methylation | 2021-2025 | 73 | CN 35 | 98.18 |
| Circular RNAs in diseases | 2021-2025 | 37 | CN 26 | 98.90 |
| Extracellular vesicles in disease | 2021-2025 | 68 | CN 46 | 98.23 |
| Ferroptosis and cancer prognosis | 2021-2025 | 81 | CN 60 | 98.35 |
| Wnt/β-catenin signaling in development and cancer | 2021-2025 | 6 | CN 2 | 95.12 |
| Peptidase Inhibition and Analysis | 2021-2025 | 102 | CN 21 | 97.31 |
| Immune cells in cancer | 2021-2025 | 187 | CN 108 | 96.05 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 640 | CN 122 | 97.57 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 403 | CN 66 | 97.37 |
| Cancer Mechanisms and Therapy | 2021-2025 | 80 | CN 27 | 93.97 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 242 | CN 77 | 93.29 |
| RNA Research and Splicing | 2021-2025 | 414 | CN 118 | 92.21 |
| interferon and immune responses | 2021-2025 | 252 | CN 140 | 91.12 |
| Lung Cancer Research Studies | 2021-2025 | 475 | CN 90 | 94.53 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | 2021-2025 | 443 | CN 99 | 93.13 |
| Autophagy in Disease and Therapy | 2021-2025 | 336 | CN 167 | 90.80 |
| Cell Adhesion Molecules Research | 2021-2025 | 146 | CN 16 | 88.22 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 133 | CN 23 | 88.67 |
| Cancer-related Molecular Pathways | 2021-2025 | 254 | CN 39 | 88.46 |
| Cytomegalovirus and herpesvirus research | 2021-2025 | 444 | CN 45 | 85.53 |
| Viral-associated cancers and disorders | 2021-2025 | 428 | CN 82 | 86.93 |
| Cancer Cells and Metastasis | 2021-2025 | 923 | CN 197 | 84.00 |
| Inflammasome and immune disorders | 2021-2025 | 686 | CN 323 | 84.93 |
| Hippo pathway signaling and YAP/TAZ | 2021-2025 | 161 | CN 72 | 82.51 |
| Congenital Diaphragmatic Hernia Studies | 2021-2025 | 750 | CN 53 | 80.87 |
| Histone Deacetylase Inhibitors Research | 2021-2025 | 779 | CN 227 | 77.07 |
| Infectious Diseases and Tuberculosis | 2021-2025 | 577 | CN 64 | 77.57 |
| Cancer Diagnosis and Treatment | 2021-2025 | 879 | CN 83 | 74.73 |
| Cancer, Stress, Anesthesia, and Immune Response | 2021-2025 | 301 | CN 117 | 75.65 |
| Molecular Biology Techniques and Applications | 2021-2025 | 619 | CN 169 | 74.81 |
| Galectins and Cancer Biology | 2021-2025 | 493 | CN 124 | 74.67 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 890 | CN 368 | 73.50 |
| Eosinophilic Disorders and Syndromes | 2021-2025 | 849 | CN 61 | 75.12 |
| Inflammatory Myopathies and Dermatomyositis | 2021-2025 | 664 | CN 101 | 74.99 |
| Diagnosis and treatment of tuberculosis | 2021-2025 | 731 | CN 88 | 66.96 |
| Kruppel-like factors research | 2021-2025 | 818 | CN 329 | 49.80 |
| FOXO transcription factor regulation | 2021-2025 | 310 | CN 116 | 47.77 |
| Calcium signaling and nucleotide metabolism | 2021-2025 | 648 | CN 126 | 45.00 |
| NF-κB Signaling Pathways | 2021-2025 | 574 | CN 234 | 46.04 |
| Redox biology and oxidative stress | 2021-2025 | 778 | CN 208 | 33.97 |
